AbbVie To Build On Relationship With Calibr Via Five-Year Extension

 
• By Joseph Haas

Deal Snapshot: Previously partnered on CAR-T therapies for cancer and COVID-19 antivirals, AbbVie and Scripps’ discovery unit Calibr unveil a five-year extension, including new targets and preclinical candidates.

AbbVie exterior
AbbVie continues its discovery alliance with Calibr/Scripps Research • Source: Alamy

Who: AbbVie/Calibr – Scripps Research Institute

What: AbbVie and the institute’s drug discovery unit are building upon existing collaborations, giving the pharma option rights to new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business